In this review:
First-line atezolizumab/vemurafenib/cobimetinib for BRAF V600 melanoma
Cemiplimab for advanced cutaneous SCC
Nivolumab ±ipilimumab in resected stage IV melanoma with no apparent disease
Managing early melanoma recurrence despite adjuvant anti-PD-1 therapy
Optimal neoadjuvant ipilimumab/nivolumab schedule in macroscopic stage III melanoma
Keratinocyte cancer with incidental perineural invasion
Melanoma in organ transplant recipients
Predictors of recurrence, metastasis and death from primary BCC ≥2cm
Improved risk prediction for SNLB-positivity in melanoma
Melanoma risk in biologic recipients with inflammatory diseases
Please login below to download this issue (PDF)